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SURGERY FOR ACQUIRED 
HEART DISEASE 
FOURTEEN-YEAR 
EXPERIENCE WITH 
HOMOVITAL HOMOGRAFTS 
FOR AORTIC VALVE 
REPLACEMENT 
Two hundred seventy-five unprocessed, viable homograft ("homovital") aortic 
valves were used for aortic valve replacement in patients aged 1.5 to 79 years 
(mean 45.8 - 19 years) with maximum follow-up of a 14-year period (mean 4.8 
years). Ninety-two percent (252 patients) had New York Heart Association 
class HI or IV functional status before operation and 25 underwent emergency 
operation. Valves were harvested under sterile conditions and kept in nutrient 
medium 199. Freehand (subcoronary) technique was used in 147 patients and 
freestanding root replacement was used in 128. Cumulative survival rates for 
the whole group were 92% -+ 2% at 5 years and 85% - 3% at 10 years, as 
compared with 96% -+ 2% and 94% -+ 4%, respectively, for the 98 patients who 
underwent isolated root replacement. Multivariate analysis determined that 
root replacement with associated procedures and operation for prosthetic 
endocarditis were risk factors for death, whereas previous xenograft valve, 
operation for endocarditis, and operation for aortic regurgitation were risk 
factors for reoperation. Actuarial rates for freedom from degenerative alve 
failure diagnosed at operation, by postmortem examination, or by routine 
echocardiography were 94% +- 2% at 5 years and 89% - 3% at 10 years. 
Recipient age younger than 30 years and previous xenograft valve were risk 
factors for late degeneration. We conclude that homovital valves demonstrate 
good durability, particularly in patients older than 30 years, who had a 10-year 
freedom from degeneration rate of 97%. (J THORAC CARDIOVASC SURG 1995; 
110:186-94) 
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1-o  date there is no ideal aortic valve substitute. 
/Homogra f t  aortic valves offer many theoretic and 
proven advantages, which include restoration of 
normal flow in the aortic root, sinuses, and coronary 
orifices; lack of thromboembolism; and resistance to 
infection. 1-3 These valves also have several disadvan- 
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tages, however, which include a slightly more com- 
plex technique of insertion, limited availability, and 
limited durability. The last factor is the most impor- 
tant because it necessitates reoperation, with atten- 
dant risk, inconvenience, and cost. Two of the most 
important determinants of durability are the meth- 
ods of sterilization and methods of preservation of 
the homograft. Earlier methods, which include 
chemical (B propriolactone) preservation, irradia- 
tion,4, s and freeze drying, 6have been shown to have 
a profound deleterious effect on the long-term per- 
formance of the homograft valve. In more recent 
years, antibiotic sterilization 7-9 and cryopreserva- 
tion 1~ have resulted in significant improvements 
in long-term performance of homograft valves. 
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These improvements have been attributed to pre- 
served "viability" of the component cells of the 
homograf t )  ~We and others have shown that cells in 
the homograft  cusp express major histocompatibil ity 
antigens both in human beings 13 and in experimen- 
tal animals14; however, "viability" could alter the 
immunologic behavior of the valve. This concern has 
prompted the suggestion that immunosuppressive 
agents, with all their potentially serious side effects, 
could be indicated in patients receiving a viable 
valve) 5 All forms of valve processing, including 
antibiotic steri l ization.and cryopreservation, have 
the  potentia ! to alter the viability as well as the 
physical and antigenic properties of the valve. To 
establish the effects of each form of sterilization on 
long-term functionality of the aortic homograft, it is 
essential to determine the behavior of the unproc - 
essed, fully viable homograft. The purpose of this 
article is to analyze our experience with aortic 
homograf ts - -harvested under  sterile conditions 
from cardiac transplant recipients or brain dead  
multiorgan donors, kept in tissue-culture medium, 
and inserted at the first available opportuni ty- - to  
determine their long-term performance and attempt 
to define determinants of patient survival ikelihood 
and valve function. 
Patients and methods 
Between February 1980 and October 1993, 275 patients 
underwent aortic valve replacement with unprocessed, 
viable homograft ("homovital") aortic valves. Their ages 
ranged from 1.5 to 79 years (mean 45.8 +- 19 years). 
Twenty-two (8%) were aged' 16 years or younger. There 
were 188 (68.4%) male and 87 (31.6%) female patients. 
The indication for operation was aortic stenosis in 96 
patients, aortic regurgitation i  123 patients, and mixed 
lesions in 56 patients. Twenty-three patients had New 
York Heart Association (NYHA) functional class II sta- 
tus, 162 had class III status, and 90 had class IV'status. 
The operation was performed electively in 250 cases and 
as an emergency procedure in 25 cases. Pertinent patient 
data, as well as variables relating to the homograft valve 
and the operation, are given in the Appendix. 
Homograft data. The homograft valves ,were harvested 
under sterile conditions from cardiac transplant recipients 
in 224 cases and from brain-dead multiorgan donors in 51 
cases. The donors varied in age from 10 to 66 years (mean 
42 _+ 13 years). The original disease of the cardiac 
transplant recipients was isehemic heart disease in 93 
cases, cardiomyopathy in 101 cases, congenital heart 
disease in 14 cases, and other diseases in 16 cases. The 
valves were immediately placed in 199 tissue culture 
medium containing extremely small doses of penicillin 
and kept at 4~ until used at the first opportunity. The 
interval of time between harvesting and insertion varied 
from 2 hours to 60 days (mean 3.9 - 7 days), with the vast 
Number of Valves (n=275) 
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Fig. 1. Interval between harvesting and insertion of the 
homografts. 
majority inserted within 3 days of harvest (Fig. 1). All 
donors were seronegative for human immunodeficiency 
virus and hepatitis B surface antigen. 
Insertion technique. The valves were inserted as free 
homografts in the subcoronary position by means of a 
two-suture line technique 4 with a lower interrupted and 
upper continuous suture line in 147 patients (53.5%). This 
technique was used if the available valve matched the size 
of the patient's aortic root, with a diameter equal to or 
(ideally) 1 to 2 mm smaller than that of the patient's aortic 
root. The remaining 128 patients underwent replacement 
of the aortic root with implantation of the coronary 
arteries) 6 This technique was used when there was a 
mismatch in size or shape between the homograft and the 
patient's aortic root and in patients with aortic root 
disease) 7 
Follow-up and data analysis. At the end of the study in 
March 1994, there were nine early (-<30 days after 
operation) and 16 late deaths. Of the remaining 250 
patients, 13 could not be traced. The status of 34 was 
determined by means of mailed questionnaires and tele- 
phone contact, whereas the remaining 203 patients were 
seen at our hospital during the period of July 1993 
through March 1994. The follow-up investigation i cluded 
physical examination, electrocardiography, and chest ra- 
diography. In addition, echo Doppler studies, including 
color-flow mapping, were performed in 197 patients. 
Aortic regurgitation was classified as absent or in one of 
four grades: trivial, mild, moderate, and severe. Presumed 
degenerative Valve failure was defined as moderate or 
severe valve malfunction discovered at reoperation or 
post mortem examination, as well as moderate or severe 
regurgitation or stenosis (with a gradient of ->50 mm Hg) 
diagnosed by routine echo Doppler imaging in the ab- 
sence of previous or current endocarditis. 
Statistical analysis. BMDP computer programs 18 were 
used for the statistical analyses. Simple comparisons be- 
tween groups were done by use of a one-way analysis of a 
nonpaired t test variance or a standard (Pearson))(2 test as 
appropriate. Linear relations were checked by a standard 
least-squares correlation analysis. The Kaplan-Meier 
product-limit method was used in the estimation of long- 
term survival and event-freedom (freedom from valve 
related complications) probability curves; differences be- 
tween curves were checked by the log-rank (Mantel-Cox) 
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Fig. 2. Cumulative survival rates of all patients undergoing homovital homografl aortic valve replacement, 
including early death. Numbers above the abscissa indicate patients at risk at 1, 5, and 10 years. Five- and 
10-year survival rates plus or minus SEM are given. 
and the generalized Wilcoxon (Gehan) tests. Long-term 
survival and event-freedom estimates are given plus or 
minus one standard error of the mean (SEM). Multivari- 
ate analysis of long-term survival and freedom from 
valve-related complication rates was performed with the 
proportional hazard regression model introduced by 
Cox. 19 W e adhered strictly to a comprehensive, formal- 
ized analysis sequence as described elsewhere. 2~ The 
formalized analysis equence was developed to make the 
regression models as reproducible as possible. Variables 
considered in the tests are given in the Appendix. The 
level of significance was set at 0.05. 
Resu l ts  
Survival. Among all patients, the cumulative sur- 
vival rates were 95% --- 1% at 1 year, 92% --_ 2% at 
5 years, and 85% ___ 3% at 10 years (Fig. 2). Patients 
who underwent isolated aortic root replacement had 
survival rates of 96% --- 2% at 5 years and 94% + 
4% at 10 years (Fig. 3). These rates were slightly but 
not significantly better than those in patients who 
underwent isolated aortic valve replacement by 
means of the freehand two-suture line technique, 
who had survival rates of 93% _+ 3% at 5 years and 
88% ___ 5% at 10 years. In contrast, patients who 
underwent associated procedures in combination 
with root replacement or subcoronary insertion of 
aortic homografts had significantly (p = 0.05) lower 
long-term survival rates, 86% ___ 4% at 5 years and 
77% ___ 7% at 10 years (Fig. 3). Similarly, patients 
older than 70 years had a 5-year survival rate of 
71% + 12%, compared with 93% --- 2% for those 
younger than that age (p = 0.004). Multivariate 
,analysis of possible determinants of long-term sur- 
vival identified operation for prosthetic endocarditis 
(p = 0.01) and root replacement with associated 
procedures (p = 0.03) as risk factors. The observed 
10-year survival rate among patients free of any of 
these risk factors (n = 187) was 91% _+ 3%. 
Reoperation. Eight Patients underwent reopera- 
tion with replacement of the homograft, with an- 
other homograft in four and with a prosthetic Valve 
in four, with, no deaths. The interval between the 
first and second operations was 1.6 to 8.2 years 
(mean 5.2 + 2 years). The cause of valve dysfunction 
was endocarditis n six patients and degeneration i  
two. The cumulative rates for freedom from reop- 
eration for any cause were 98% - 1% at 5 years and 
91% +- 4% at 10 years, with a linearized incidence 
rate of 0.61% per patient-year (Fig. 4). Multivariate 
analysis determined previous xenograft aortic valve 
replacement, operation for pure aortic regurgita- 
tion, and operation for endocarditis to be risk 
factors for reoperation (Table I). 
Degenerative valve failure. The total rates of 
freedom from presumed egenerative valve failur~ 
(previously defined), including failures discovered at 
operation, by post mortem examination, and by 
routine echocardiography, were 94% +_ 2% at 5 
years and 89% ___ 3% at 10 years. The linearized 
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Fig. 3. Cumulative survival rates after homovital homograft aortic valve replacement with root replace- 
ment, freehand two-suture line technique (subcoronary), or either technique with associated procedures. 
Risk values presented as in Fig. 2. 
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Fig. 4. Cumulative rates for freedom from reoperation i all patients. Risk values presented as in Fig. 2. 
incidence rate for the first 7 postoperative y ars was 
0.89% per patient-year, whereas that for the interval 
between postoperative y ars 7 and 14 was 2.58% per 
patient-year. Donor age younger than 25 years or 
older than 55 years and recipient age younger than 
30 years tended to increase the rate of degeneration. 
Multivariate analysis identified recipient age younger 
than 30 years and previous xenograft aortic valve 
replacement ,,as risk factors for late degeneration 
(Table II); 190 patients without either risk factor 
had a 10-year freedom from valve degeneration rate 
of 97% + 2%. 
Thromboembol i sm and endocard i t i s .  There were 
three episodes of thromboembolism resulting in 
transient hemiparesis in elderly patients, with no 
permanent sequelae. Routine postoperative antico- 
agulation therapy was not used. Seven patients had 
endocarditis at periods varying between 1.6 and 5.8 
years (mean 4.1 z 2.1 years) after operation. The 
freedom from endocarditis rates were 98% -'- 1% at 
5 years and 94% _+ 2% at 10 years, with a linearized 
rate of 0.53% per patient-year. Multivariate analysis 
determined operation for native or prosthetic endo- 
carditis and previous xenograft aortic valve replace- 
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Table I. Determinants of reoperation 
Covariates b SEM p 
Previous xenograft AVR 3.01 1.23 0.01 
Pure AR 1.93 0.78 0.05 
Primary operation for endocarditis 1.71 1.00 0.03 
Global X 2, p = 0.0001. AVR, Aortic vaive replacement~ AR, aortic 
regurgitation. 
Table II. Determinants of valve degeneration 
Covariates b SEM p 
Age <30 yr 1.58 0.59 0.007 
Previous xenograft AVR 1.28 0.61 0.05 
Global)r 2, p = 0.0005. A VR, Aortic valve replacement. 
ment to be risk factors for the development of late 
endocarditis (Table III). 
All valve-related complications. The rates of 
freedom from all valve-related complications (reop- 
eration, degeneration, endocarditis, and thrombo- 
embolism) were 92% ___ 2% at 5 years and 80% • 
5% at 10 years for all patients. Multivariate analysis 
showed endocarditis, previous xenograft replace- 
ment of the aortic valve, and age younger than 30 
years to be risk factors for all complications (Table 
IV). The rate for 10-year freedom from valve- 
related complications for 180 patients with none of 
these risk factors was 94% • 3%. 
Discussion 
This study shows that the use of homovital (un- 
processed) homografts to replace the aortic valVe or 
root gives good early and medium-term results, 
which compare favorably with those for the use of 
"processed" valves. It also shows, however, that the 
use of fully viable valves does not eliminate the risk 
of slow, late degeneration, and several risk factors 
for late degeneration or death were found. The 
pattern of survival rates after homovital homograft 
replacement reflects the low operative risk, particu- 
larly for patients undergoing isolated valve or root 
replacement, who had a 30-day mortality rate of 
0.6%, as well as the low late mortality for the whole 
group. This low risk was particularly apparent for 
patients of any age undergoing isolated root re- 
placement, who had a 10-year survival rate, includ- 
ing in-hospital deaths, of 94% _+ 4%. The good 
long-term survival rate could be related in part to 
the nearly normal flow pattern in the root of the 
aorta, which may help maintain coronary flow and 
ventricular function, as well as to the low valve 
fi~ilure rate during the period of follow-up. In this 
Table III. Determinants of endocarditis 
Covariates b SEM p 
Native/prosthetic endocarditis 2.96 0.77 0.001 
Previous xenograft AVR 1.91 0.87 0.03 
Global x z, p = 0.0001. AVR, Aortic valve replacement. 
Table IV. Determinants of all complications 
Covariates b SEM p 
Endocarditis 1.66 0.53 0.002 
Previous xenograft AVR 1.36 0.57 0.57 
Age <30 yr 1.32 0.47 0.005 
Global )r p = 0.0001. AVR, Aortic valve replacement. 
series, the only criterion for inclusion was the avail 
ability of a homovital Valve; no patient was excludec 
because of advanced age or poor clinical condition 
This selection pattern is reflected by the fact that 2: 
patients were operated on on an emergency basi: 
and 90 patients had NYHA class IV functiona 
status. Long-term survival rate appeared to be ad 
versely affected by the need for additional proce 
dures, age 70 years or older, and poor left ventric 
ular function before operation. 
One of the most important determinants of th~ 
results of valve replacement with tissue valves i~ 
durability. Durability can be affected by the qualiE 
of the tissue, the method of preparation and inser 
tion, and any reaction from the host's immune 
system. Before insertion, unprocessed tissue ho 
mografts have ideal design, physical characteristics 
and biologic characteristics. Processes aimed a' 
maintaining sterility and allowing storage can alte~ 
the biologic, physical, and antigenic properties o: 
the valve. 21-a8 The aortic valve and wall express, 
major histocompatability antigens as well as adhe- 
sion molecules; this indicates their capacity to stim. 
ulate and be a target for humoral as well as cell. 
mediated immune response. 13' 14,26 However, the 
exact effects of any possible immunologic damage 
on long-term function of the homograft have no1 
been determined in clinical series. On theoretic 
grounds, the fact that the aortic valve is avasculal 
and the suggestion that the aortic root is immuno. 
logically "privileged" could have important roles ir 
slowing down or halting immune-mediated damage 
Furthermore, recent series that used relatively via- 
ble valves -12 showed improved results. These resulL, 
support he notion that immune damage may play 
minor role. Our study is the first relatively large 
study to evaluate the performance of a truly viable, 
_unprocessed homograft. In this series, most (98%) 
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Fig. 5. Predicted freedom from valve degeneration in two hypothetic patients, one aged 15 years and the 
other aged 70 years, after either isolated root replacement or subcoronary valve replacement bymeans of 
the two-suture line technique. See text for other details. 
but not all of the valves were used within 3 days and 
therefore can be regarded as "homovital" from the 
biologic standpoint. The rate of degeneration i
these valves has been slow, with no evidence of 
accelerated failure caused by rejection. We used a 
rigorous et of criteria to define presumed egener- 
ative valve failure; these criteria were designed to 
include all patients with significant, nonendocardi- 
tis-induced valve dysfunction discovered during rou- 
tine echocardiographic examination, atreoperation, 
or after death. The rates of freedom from this 
complication i the whole series were 94% _+ 2% at 
5 years and 89% + 2% at 10 years, which compare 
favorably with those in other series that used pro- 
cessed homografts, 4' 5.8-12 This correspondence in-
dicates that true viability is an advantage. The use of 
these valves, however, has resulted in a definite but 
slow rate of degeneration, 0.89% per patient-year 
during the first 7 years accelerating to 2.58% per 
patient-year during the Second 7-year period. These 
data indicate that "homovital" valves are subject o 
rejection or are affected by other biochemical or 
hemodynamie factors. The rate of degeneration i  
the longer term and its determinants need to be 
studied further. Matching for ABO blood group did 
not appear to influence the rate of degeneration 
during the period of follow-up, and the role of HLA 
matching could not be determined because of the 
small number of samples that have been processed 
at this point; this factor is the subject of a longer 
term study. The higher incidence of late degenera- 
tion among younger ecipients, as well as after the 
use of valves from younger donors, could be caused 
by differences in the immune systems of children 29 
and the increased cellularity of homografts from 
younger donors. 3~ Despite the faster ate of degen- 
eration of homografts in children than in adults, 
homografts inserted in children function for longer 
periods than do xenografts 31 and do not appear to 
adversely affect long-term survival because of their 
slow mode of failure and the low risk of reoperation. 
We therefore believe that, at least for the time 
being, homovital homografts should be considered 
as an alternative to pulmonary valve autografts 32' 15 
in this age group. Aortic root replacement allows the 
insertion of adult-sized homografts in even small 
children. 17 Reoperation after aortic root replace- 
ment can be achieved with low morbidity and mor- 
tality rates. 33 We are currently evaluating the use of 
homografts versus autografts in this age group in a 
prospective randomized trial. 
In this series, previous xenograft replacement of
the aortic valve appeared to increase the rate of late 
degeneration f the homovital valve. This finding is 
.difficult to explain and needs to be validated or 
challenged in the future. It is possible, however, that 
previous xenograft valves can alter the immunologic 
behavior of the host or the hemodynamic perfor- 
mance of the homograft as a result of distortion of 
the aortic root. Homovital valves appear to give 
excellent results in patients older than 30 years who 
did not have a previous xenograft valve, with a rate 
for freedom from presumed egenerative alve fail- 
ure of 97% _+ 2%. 10 years after operation. 
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By means of the Cox regression model, in an 
attempt o evaluate the expected performance of 
homovital valves for patients with different charac- 
teristics, we estimated the probabilities for a 15- 
year-old boy who had undergone, previous valvot- 
omy for congenital aortic stenosis, had NYHA class 
II functional status as a result of severe aortic 
regurgitation, and underwent isolated root replace- 
ment with a valve from a donor aged 25 years. The 
estimated 10-year survival probability was 93%, and 
the probability of freedom from presumed egener- 
ative valve failure at 10 years was 73% if root 
replacement was used and 63% if the two-suture 
line technique was used (Fig. 5). In contrast, the 
estimated 10-year survival probability for a 70-year- 
old man who had severe aortic stenosis, had NYHA 
class III functional status, and underwent isolated 
root replacement with a valve from a 50-year-old 
donor was 87%, with a probability of freedom from 
presumed egeneration at 10 years of 97% (Fig. 5). 
The 10-year rate for freedom from endocarditis 
observed in our study (94%) is identical to that 
previously reported after the use of antibiotic-ster- 
ilized or cryopreserved homografts. 1~ ~a 
Multivariate analysis identified operations for en- 
docarditis and previous xenograft replacement of 
the aortic valve as risk factors for late endocarditis. 
This suggests an altered immune system or persis- 
tence of infection in these patients. 
Eighty percent of the valves used in this series 
were obtained from cardiac transplant recipients. 
These patients were studied extensively before op- 
eration with regard to both valve function and 
presence or absence of bacterial or viral infection. 
Although a significant number (n = 101) underwent 
transplantation for cardiomyopathy, which is known 
to be associated with persistance of a coxsackievirus 
genome in the myocardium in a number of pa- 
tier~ts, 34 this virus is altered, and because it has lost 
its capacity to replicate it is r~ot infective. This 
conclusion is supported by our clinical observations. 
Transplant recipients therefore represent an impor- 
tant additional source of homograft valves. 35 
This study has shown that the interval between 
harvesting and insertion does not appear to affect 
outcome. This could be because most of the valves 
were inserted within 48 hours and the Period ot 
follow-up and the number of events were not suffi- 
ciently large to show such an effect. This is an on-going 
study to determine the effects of these factors as well as 
of others, including HLA matching, on outcome. We 
hope that the data presented in this article are useful 
in guiding clinical practice, as well as evolving new 
strategies for improving long-term performance of the 
grafts in the high-risk groups for failure without in- 
creasing the risk to patients. 
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Discuss ion 
Dr. Antonio F. Corno (Milan, Italy). I have two ques- 
tions, Mr. Yacoub. Firs[, did you observe fast degenera- 
tion in the pediatric population, associated with the need 
for early homograft replacement? Second, do you suggest 
any low age limit for the use of this type of "homovital" 
homograft? 
Mr. Yacoub. These are very relevant questions. We 
believe that although the rate of degeneration i  children 
is faster than in adults, it is still acceptable and is so much 
better than that for xenografts. In addition, we have shown 
that reoperation with the use of another homograft carries 
a low risk and is followed by excellent long-term survival. 
Therefore multiple valve replacements could enable the 
child to reach adulthood, at which point the rate of 
degeneration is lower. Whether this policy produces im- 
ilar or superior results to pulmonary autograft replace- 
ment at the beginning needs to be investigated further. 
Dr. Jan M. Quaegebeur (New York, N.Y.). Mr. Yacoub , 
you have shown that the homovital grafts were usually 
used within the first 3 days after they were collected. 
However, a certain number of grafts were implanted only 
later, some of them 2 months after harvesting. Undoubt- 
edly, these grafts must have lost a degree of viability. Have 
you analyzed the influence of time between harvesting and 
implantation on valve function and later degeneration? 
Mr. Yacoub. In reply to the second question, there is no 
detectable influence of the interval between harvesting 
and insertion on either survival or valve degeneration. 
However, the number of valves inserted beyond 3 days 
after harvesting was too small to allow meaningful con- 
clusions to be made. 
Dr. Tirone E. David (Toronto, Ontario, Canada). Sir 
Madgi, I was very impressed with the actuarial survival. 
This is likely the best valve to keep the patients alive, but 
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at some point the valve begins to fail. Isn't this failure 
caused by calcification of the arterial wall of the ho- 
mograft? Don't you think that the leaflets begin to 
degenerate when the donor root or the remnants of the 
arterial wall calcify and increase the mechanical stress on 
the leaflets? 
Mr. Yacoub. In our own experience the rate of degen- 
eration after root replacement in the adult population is 
extremely low and appears to be slightly slower than that 
for the two-sutureline t chnique. The aortic wall of the 
root shows minimal or no calcification after homovital 
root replacement and certainly does not appear to influ- 
ence valve function. The opposite is probably true. 
Dr. David. Why does the graft fail earlier in younger 
patients? I thought younger patients had a more active 
immune system and the valve would calcify more readily. 
Mr. Yaeoub. With regard to the cause of the faster ate 
of degeneration i  children, it is possible that the immune 
system of the younger patient is more active. Alterna- 
tively, these patients tend to receive valves from younger 
donors. Such valves are more cellular and possibly more 
immunogeneic. In addition, biochemically, the younger 
patients, as we know from the xenograft experience, tend 
to have a different way of reacting to foreign tissue. These 
issues need to be investigated further. 
Mr. All Rahman (Manchester, England). Sir Magdi, you 
have suggested an immunologic reaction of a weak nature, 
an immunologic reaction especially when xenografts have 
been used in the past in the same patient. Would you 
consider using a mild form of immunosuppression n some 
of these patients to avoid rejection and consequent valve 
dysfunction? 
Mr. Yaeoub. With regard to the finding of faster 
degeneration of homografts in patients who had previous 
xenograft replacement, i  is possible that local or immu- 
nologic factors could be operative. We believe that this 
finding needs to be confirmed or refuted in future studies. 
The other point relates to immunosuppression. We be- 
lieve that the currently available immunosuppressive 
agents have many serious ide effects that would be much 
more important than the slow rate of degeneration of the 
valve even in the high-risk groups. In contrast, manipula- 
tions of the homograft tissue before insertiOn with a view 
to altering the immune response to such tissue might be a 
possibility for the future. 
Dr. Entire Bodnar (Pinner, Middlesex, United Kingdom). 
I have two questions. First, do you have any evidence that 
these valves, which are called homovital and you imply 
would be viable, are truly viable? Second, you attributed 
the failure of these valves to an immunologic reaction. 
Have you seen any evidence of rejection--macroscopic, 
microscopic, or histochemical--in those valves that you 
have removed? 
Mr. Yaeoub. With regard to the question of viability, 
these valves were dissected within minutes of procure- 
ment from the donor at the time of transplantation a d 
kept in tissue culture medium until inserted, generally 
within 3 days. Solid organs like kidneys treated in a similar 
fashion are known to be fully viable: As for the evidence 
for immunologic reaction, this needs further studies. We 
have data showing that after homovital homograft re- 
placement, anti-HLA antibodies are formed, which ap- 
pear to be donor-specific. However, the possible ffect of 
such reaction on long-term performance has yet to be 
investigated. 
Dr. Bodnar. My reason for asking these questions was 
that your statements and conclusion contradict the entire 
current concept of preserving homografts. If valves are 
stored in a nutrient solution for more than 48 hours, many 
people, such as Marc O'Brien and others, would say that 
those valves are no longer viable. They have laboratory 
evidence, not a personal belief, but scientifically sound 
laboratory evidence, to prove that viability is definitely lost 
after 7 days. 
Mr. Yacoub. In the current study we speculated that an 
immune response is involved by exclusion. In this series, 
the valves were obtained under sterile conditions-and 
were not subjected to high concentrations of antibiotics at 
any time. They were used within 3 days in almost all cases 
and therefore were truly viable. 
Appendix 
Preoperative patient-related, homograft-related, and 
intraoperative data considered in the multivariate analy- 
ses (number of patients or mean +-. standard deviation) 
Patient-related data: M~/le (n = 188) or female (n = 87) 
sex; age (46 • 19 years); NYHA functional class II (n = 
23), III (n = 162), or IV (n = 90); left ventricular 
end-diastolic dimension (58 • 13 mm) and fractional 
shortening (33% -+ 12%) at echocardiography; previous 
'aortic valve procedure, none (n = 189), homograft (n = 
32), or autograft (n = 2) aortic valve replacement, valvot- 
omy or repair/resuspension (n = 29), and xenograft (n = 
14) or mechanical valve (n = 9) aortic valve replacement; 
dominant aortic valve or prosthetic Valve lesion, stenosis 
(n = 96), regurgitation ( = 122), and mixed lesion (n = 
57); native (n = 11) or prosthetic valve (n = 7) endocar- 
ditis; original congenital (n = 25), bicuspid (n = 77), 
rheumatic (n = 33), calcific (n = 54), infectious (n = 23), 
and other or undetermined (n = 54) etiology or Marfan 
syndrome (n = 9). 
Homografi-related data. Donor age (42 • 13 years); 
male .(n = 221) or female (n = 54) donor sex; any 
combination of donor-recipient sex; donor diagnosis, car- 
diomyopathy (n = 101), ischemic heart disease (n = 93), 
congenital heart disease (n = 14), emphysema nd cor 
pulmonale (n = 13), cystic fibrosis and cor pulmonale 
(n = 3), brain:dead multiorgan donor (n = 51); donor- 
recipient ABO compatible (n = 129), incompatible (n = 
100), "feasible" (n = 46; O to A, B or AB); time from 
harvest o implantation (3.9 + 6.6 days). 
Intraoperative data. Operative procedure, subcoronary 
aortic valve replacement isolated (n = 88) or with associ- 
ated operation (n = 59), root replacement isolated (n = 
89) or with associated operation (n = 3~); associated 
operation, none (n = 189), mitral valve replacement (n = 
6) or repair (n = 10), coronary artery bypass (n = 45) 
tailoring of ascending aorta (n = 20), repair of congenita] 
malformation (n = 12) or combinations (n = 5); elective 
(n = 250) or emergency (n = 25) operation. 
